Daiichi Sankyo Co (4568.T) Stock Price

Currency:

Daiichi Sankyo Co Price

🇯🇵JPX·CLOSED

2,854.50JPY

Market closed

Today +/-

+5.50 JPY

Today %

+0.19 %

Daiichi Sankyo Co (4568.T) — ISIN JP3475350009. The Daiichi Sankyo Co stock price was 2,854.5 JPY in 2026. Revenue was 2.17 T JPY. Earnings were 323.03 B JPY. P/E ratio was 16.77. Daiichi Sankyo Co operates in the Health sector.

Daiichi Sankyo Co stock price

Ex-Dividend

Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Daiichi Sankyo Co over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Daiichi Sankyo Co stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Daiichi Sankyo Co's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Daiichi Sankyo Co Stock Price History

Date	Daiichi Sankyo Co Price
3/11/2026	2,854.50 JPY
3/9/2026	2,849.00 JPY
3/6/2026	2,867.00 JPY
3/5/2026	2,844.00 JPY
2/27/2026	3,064.00 JPY
2/26/2026	3,051.00 JPY
2/25/2026	2,995.50 JPY
2/24/2026	2,978.00 JPY
2/20/2026	2,918.50 JPY
2/19/2026	2,941.00 JPY
2/18/2026	2,939.00 JPY
2/17/2026	2,950.50 JPY
2/16/2026	2,955.00 JPY
2/13/2026	2,937.50 JPY
2/12/2026	2,906.00 JPY

API Docs Get API Key

Daiichi Sankyo Co Revenue, EBIT, Net Income

3 Years
5 Years
10 Years
25 Years
Max

Unlock the full history with 30+ years of data and forecast estimates.

Unlock all data — PRO

Revenue

EBIT

Net Income

Details

API Docs Get API Key

Daiichi Sankyo Co Income Statement, Balance Sheet, Cash Flow Statement

Last updated Mar 12, 2026, 10:14 AM

REVENUE (T JPY)

REVENUE GROWTH (%)

GROSS MARGIN (%)

GROSS INCOME (T JPY)

NET INCOME (B JPY)

NET INCOME GROWTH (%)

DIVIDEND (JPY)DIV. (JPY)

DIVIDEND GROWTH (%)DIV. GROWTH (%)

SHARES (B)

DOCUMENTS

2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e	2027e	2028e
0.93	0.93	0.88	0.84	0.95	0.97	0.94	1	1.12	0.92	0.99	0.96	0.96	0.93	0.98	0.96	1.04	1.28	1.6	1.89	2.17	2.38	2.63
–	0.39	-5.31	-4.31	13.06	1.60	-2.97	6.30	12.06	-17.78	7.30	-3.18	0.53	-3.17	5.60	-1.96	8.56	22.36	25.28	17.77	15.25	9.69	10.31
68.60	71.47	73.35	74.54	70.80	70.88	71.38	68.57	64.02	64.86	67.70	63.42	63.96	60.78	65.04	64.85	66.19	71.57	74.07	77.96	67.64	61.67	55.90
0.64	0.66	0.65	0.63	0.67	0.69	0.67	0.68	0.72	0.6	0.67	0.61	0.61	0.57	0.64	0.62	0.69	0.91	1.19	1.47	1.47	1.47	1.47
87.34	78.55	97.66	-215.5	41.85	70.12	10.38	66.62	60.94	322.12	82.28	53.47	60.28	93.41	129.07	75.96	66.97	109.19	200.73	295.76	323.03	386.37	467.8
–	-10.07	24.33	-320.66	-119.42	67.55	-85.19	541.64	-8.52	428.56	-74.46	-35.02	12.75	54.95	38.18	-41.15	-11.83	63.04	83.84	47.34	9.22	19.61	21.07
80.00	20.00	75.00	70.00	60.00	60.00	60.00	60.00	60.00	60.00	65.00	70.00	70.00	70.00	48.50	27.00	28.50	35.00	60.00	69.00	39.00	143.70	173.49
–	-75.00	275.00	-6.67	-14.29	–	–	–	–	–	8.33	7.69	–	–	-30.71	-44.33	5.56	22.81	71.43	15.00	-43.48	268.46	20.73
0.73	0.73	0.72	0.71	0.7	0.71	0.71	0.71	0.71	0.71	2.07	2.02	1.99	1.95	1.95	1.94	1.92	1.92	1.92	1.9	1.9	1.9	1.9
–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Daiichi Sankyo Co generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Daiichi Sankyo Co retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Daiichi Sankyo Co's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Daiichi Sankyo Co has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Daiichi Sankyo Co's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

ASSETS

CASH BALANCE (B JPY)

RECEIVABLES (B JPY)

OTHER RECEIVABLES (B JPY)OTHER REC. (B JPY)

INVENTORIES (B JPY)

OTHER CURRENT ASSETS (B JPY)OTHER CURRENT LIAB. (B JPY)

CURRENT ASSETS (T JPY)

TANGIBLE ASSETS (B JPY)

LONG-TERM INVESTMENTS (B JPY)LONG-T. INVEST. (B JPY)

LONG-TERM RECEIVABLES (B JPY)LONG-T. REC. (B JPY)

INTANGIBLE ASSETS (B JPY)INTANGIBLE ASSETS (B JPY)

GOODWILL (B JPY)

OTHER NON-CURRENT ASSETS (B JPY)OTHER NON-CURRENT ASSETS (B JPY)

NON-CURRENT ASSETS (T JPY)

TOTAL ASSETS (T JPY)

LIABILITIES

COMMON STOCK (B JPY)

ADDITIONAL PAID-IN CAPITAL (B JPY)

RETAINED EARNINGS (T JPY)

OTHER EQUITY (B JPY)OTHER EQUITY (B JPY)

UNREALIZED GAINS/LOSSES (B JPY)UNREAL. GAINS/LOSSES (B JPY)

EQUITY (T JPY)

LIABILITIES (B JPY)

PROVISIONS (B JPY)

OTHER SHORT-TERM LIABILITIES (B JPY)OTHER SHORT-TERM LIAB. (B JPY)

SHORT-TERM DEBTS (B JPY)SHORT-TERM DEBTS (B JPY)

SHORT-TERM PORTION OF LONG-TERM DEBTS (B JPY)LONG-TERM DEBT PORTION (B JPY)

SHORT-TERM RECEIVABLES (T JPY)SHORT-TERM REC. (T JPY)

LONG-TERM LIABILITIES (B JPY)LONG-T. LIAB. (B JPY)

DEFERRED TAXES (B JPY)

OTHER LIABILITIES (B JPY)OTHER LIAB. (B JPY)

LONG-TERM LIABILITIES (T JPY)LONG-T. LIABILITIES (T JPY)

DEBT (T JPY)

TOTAL CAPITAL (T JPY)

2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025

514.99	621.51	574.14	312.03	337.54	419.69	320.26	372.3	505.33	374.71	514.34	514.39	594.5	560.52	673.23	671.7	778.75	607.61	876.87	714.26
239.57	196.43	166.69	194.49	210.22	203.27	226.35	235.81	243	218.18	228.62	208.67	210.77	360.38	282.54	201.03	214.58	280.68	344.8	435.51
0	0	0	0	0	0	0	0	27.19	24.49	21.06	23.69	21.26	59.64	27.24	31.36	52.36	68.56	109.41	183.59
121.69	107.76	98.16	139.48	143.22	142.79	169.66	174.43	189.41	150.09	144.27	153.14	172.59	176.07	173.36	200.86	217.91	301.61	438.11	514.91
82.22	90.14	87.54	137.51	128.77	128.32	145.26	161.1	25.67	17.87	216.98	297.9	202.43	236.58	227.75	163.47	81.68	236.59	404.84	61.17
0.96	1.02	0.93	0.78	0.82	0.89	0.86	0.94	0.99	0.79	1.13	1.2	1.2	1.39	1.38	1.27	1.35	1.5	2.17	1.91
289.71	248.86	221.26	250.11	249.54	237.71	261.24	303.43	316.3	266.49	250.17	217.77	217.95	229.09	247.05	265.28	304.07	348.91	421.69	498.52
256.34	262.24	216.04	153.73	137.04	102.42	104.56	129.19	138.48	593.23	167.62	141.54	179.98	116.3	97.62	141.01	132.72	131.15	147.97	144.77
6.15	1.62	1.3	0.61	0	0	0	0	2.6	2.06	1.78	0.74	0.89	0.8	0.74	0.42	0.18	0.04	0	0
26.38	41.58	75.67	115.18	107.12	89.61	150.55	149.91	171.42	199.41	210.4	217.04	173.54	169.47	172.5	172.82	163.88	159.61	168.3	235.84
9.79	18.57	15.4	77.38	73.77	67.32	82.74	73.54	85.52	71.37	78.69	78.45	75.48	77.85	76.76	77.71	83.56	98.33	108.5	108.43
49.27	48.13	31.68	114.08	102.27	89.11	57.86	44.35	149.11	64.39	66.6	61.65	48.38	101.36	126.83	159.52	191.72	275.8	440.66	559.13
0.64	0.62	0.56	0.71	0.67	0.59	0.66	0.7	0.86	1.2	0.78	0.72	0.7	0.69	0.72	0.82	0.88	1.01	1.29	1.55
1.6	1.64	1.49	1.49	1.49	1.48	1.52	1.64	1.85	1.98	1.9	1.91	1.9	2.09	2.11	2.09	2.22	2.51	3.46	3.46

50	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50
179.86	179.86	179.86	105.19	105.19	105.19	105.19	105.19	105.27	105.27	103.93	103.75	94.63	94.63	94.63	94.49	0	0	1.96	0
0.94	0.97	1.03	0.76	0.75	0.78	0.75	0.77	0.72	0.99	0.99	1.01	1.03	1.15	1.24	1.28	1.17	1.23	1.39	1.46
0.74	4.96	-16.26	-51.29	-58.78	-82.44	-100.41	-59.04	121.75	169.04	146.72	124.49	120.51	115.17	82.1	111.48	168.15	200.87	284	263.69
80.25	72.36	48.54	19.88	27.46	16.56	22.31	34.21	0	0	0	0	0	0	0	0	0	0	0	0
1.25	1.28	1.29	0.88	0.87	0.87	0.82	0.9	0.99	1.32	1.3	1.29	1.3	1.41	1.47	1.53	1.39	1.48	1.72	1.77
65.6	56.44	46.41	59.42	66.54	58.41	61.82	59.8	66.54	50.05	50.97	54.76	68.81	73.47	70.15	68.69	68.54	80.39	88.74	672.72
0	0	0	0	0	0	0	88.99	0	0	0	0	0	0	0	0	0	0	0	0
157.69	216.51	148.04	184.58	182.05	172.93	262.06	221.25	233.24	226.37	307.94	271.52	263.78	270.66	231.04	255.2	295.64	397.55	621.82	646.16
13.55	8.56	0.07	261.11	15.02	25.83	71.08	45.34	67.03	0	0	0	0	0	0	0	0	0	0	0
0	0	0	3.42	5.2	49.78	0	20.73	94.38	21.08	20.79	0.54	20.52	40.42	49.88	29.68	31.09	52.33	12.84	15.11
0.24	0.28	0.19	0.51	0.27	0.31	0.39	0.44	0.46	0.3	0.38	0.33	0.35	0.38	0.35	0.35	0.4	0.53	0.72	1.33
3.37	1.53	0.02	63.82	270.92	224.04	204	200.92	265.43	203.56	182.83	281.61	261.59	221.5	216.45	196.5	182.53	140.53	143.16	140.78
23.93	36.15	26.72	5.43	29.24	28.46	52.08	45.11	39.84	88.36	33.68	32.29	18.68	17.17	15.64	17.52	12.44	12.65	12.86	11.07
82.85	45.5	22.12	28.2	31.03	33.08	34.68	46.19	80.06	85.84	70.8	102.83	131.35	215.14	216.18	245.54	280.29	379.59	893.11	926.83
0.11	0.08	0.05	0.1	0.33	0.29	0.29	0.29	0.39	0.38	0.29	0.42	0.41	0.45	0.45	0.46	0.48	0.53	1.05	1.08
0.35	0.36	0.24	0.61	0.6	0.59	0.69	0.73	0.85	0.68	0.67	0.74	0.76	0.84	0.8	0.81	0.87	1.06	1.77	2.41
1.59	1.64	1.53	1.49	1.47	1.46	1.51	1.63	1.84	1.99	1.96	2.03	2.06	2.25	2.27	2.35	2.26	2.55	3.5	4.18

Details

Balance Sheet

ⓘ

What Is the Balance Sheet?

The balance sheet is a financial snapshot of Daiichi Sankyo Co at a specific point in time. It follows the fundamental equation: Assets = Liabilities + Shareholders' Equity. Unlike the income statement (which covers a period), the balance sheet tells you what the company owns, what it owes, and what belongs to shareholders at a given date.

Assets

Current assets (cash, receivables, inventory) can be converted to cash within 12 months and indicate short-term liquidity. Non-current assets (property, equipment, intangible assets, goodwill) represent long-term investments. A high proportion of cash and short-term investments gives Daiichi Sankyo Co financial flexibility to weather downturns, fund acquisitions, or return capital to shareholders.

Liabilities

Current liabilities (accounts payable, short-term debt) are obligations due within one year. Non-current liabilities (long-term debt, pension obligations) are due further out. Key ratio to watch: the debt-to-equity ratio (Total Debt ÷ Shareholders' Equity). A ratio below 1.0 is generally healthy, meaning the company is funded more by equity than debt. Highly leveraged companies amplify both gains and losses.

Shareholders' Equity

Equity is the residual value belonging to shareholders after all debts are paid. It includes retained earnings (accumulated profits not paid out as dividends) and paid-in capital. Rising equity year over year is a positive sign — it means Daiichi Sankyo Co is building book value. Declining equity, especially when driven by losses or heavy share buybacks funded by debt, warrants closer scrutiny.

Key Ratios to Derive

From the balance sheet, you can calculate the current ratio (current assets ÷ current liabilities; above 1.5 is comfortable), book value per share (equity ÷ shares outstanding), and return on equity (net income ÷ equity; above 15 % is strong). Tracking these ratios over time reveals whether Daiichi Sankyo Co is strengthening or weakening its financial position.

NET INCOME (B JPY)

DEPRECIATION AND AMORTIZATION B JPYDEPRECIATION (B JPY)

DEFERRED TAXES (M JPY)

CHANGES IN WORKING CAPITAL (B JPY)CHANGES IN WORKING CAPITAL (B JPY)

NON-CASH ITEM (B JPY)

PAID INTEREST (B JPY)

PAID TAXES (B JPY)

Net Cash Flow from Operating Activities (B JPY)NET CASH FLOW FROM OPERATING ACTIVITIES (B JPY)

CAPITAL EXPENDITURES (M JPY)

CASH FLOW FROM INVESTING ACTIVITIES (B JPY)CASH FLOW FROM INVESTING ACTIVITIES (B JPY)

CASH FLOW FROM OTHER INVESTING ACTIVITIES (B JPY)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B JPY)

INTEREST INCOME AND EXPENSES (M JPY)

NET DEBT CHANGE (B JPY)NET DEBT CHANGE (B JPY)

Net change in equity (M JPY)NET CHANGE IN EQUITY (M JPY)

CASH FLOW FROM FINANCING ACTIVITIES (B JPY)CASH FLOW FROM FINANCING ACTIVITIES (B JPY)

OTHER ITEMS OF FINANCING CASH FLOWS (B JPY)CASH FLOW FROM OTHER FINANCING ACTIVITIES (B JPY)

TOTAL DIVIDENDS PAID (M JPY)

NET CHANGE IN CASH FLOW (B JPY)

FREE CASH FLOW (M JPY)

SHARE-BASED COMPENSATION (M JPY)

2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
136.89	126.91	166.86	-308.26	97.37	120.42	33.92	92.1	99.78	79.94	122.39	87.79	81.02	85.83	141.16	74.12	73.52	126.85	237.23	355.63
42.55	43.58	42.33	415.57	55.09	55.21	57.38	52.54	51.49	42.02	44.31	47.37	46.68	46.17	52.61	57.38	58.25	67.79	59.65	68.65
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
-45.72	38.8	-90.23	-57.21	-2.05	-26.27	-57.98	-13.24	-118.25	-19.45	2.57	-26.98	-46.07	-45.47	6.95	69.59	0.21	-81.71	316.68	-348.55
-1.29	-101.99	-50.77	28.26	-20.17	-8.22	59.25	-2.15	4.3	40.27	5.01	28.05	32.82	12.87	8.58	3.14	8.39	23.39	-18.02	-18.96
0.31	0.25	0.13	0.65	3.64	2.89	3.27	4.12	11.18	1.73	1.4	1.51	2.04	1.77	2.53	1.84	1.78	2.08	1.84	1.93
53	61.95	60.52	58.61	30.41	34.74	31.9	23.56	54.81	21.87	37.44	30.37	22.17	36.15	26.18	24.53	22.58	46.25	96.76	108.28
132.44	107.3	68.19	78.36	130.23	141.14	92.57	129.25	37.3	142.78	174.28	136.23	108.44	92.03	196.6	192.21	139.23	114.51	590.04	53.84
-48,586	-42,952	-51,586	-44,602	-31,157	-36,132	-63,700	-78,862	-54,514	-94,630	-69,397	-52,962	-38,008	-66,613	-52,565	-64,093	-76,682	-67,366	-122,791	-187,872
-39.26	45.31	-49.44	-413.85	42.63	-62.97	-125.1	-109.28	-161.37	-21.28	-5.97	-96.79	108.57	-142.52	81.67	-39.25	212.34	-257.78	-282.64	334.17
9.33	88.26	2.15	-369.25	73.78	-26.83	-61.4	-30.42	-106.85	73.35	63.43	-43.83	146.58	-75.91	134.24	24.85	289.02	-190.42	-159.85	522.04
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
-2.38	1.02	-2.38	197.32	-39.66	16.15	-18.75	-15.09	143.62	120.6	-22.98	80	0	-20	-36.41	-40.39	-34.49	-34.95	-56.46	-17.39
-13,691	-162	-33,407	-45,817	-23	-32	-11	-12	-31	-25	-50,239	-50,094	-50,084	-45	-85	-100,190	-15	-24	-25	-246,066
-50.1	-40.77	-82.9	98.06	-89.12	-25.98	-50.2	-57.33	100.32	-132.2	-122.93	-15.02	-101.77	-66.2	-91.64	-202.43	-86.23	-89.59	-123.56	-377.77
-16.71	-1.57	-0.1	-0.15	-0.18	0.15	10.81	0.01	-1.03	0.08	-1.25	-1.04	-5.26	-0.82	-9.79	-12.91	0	0	-0	0
-17,326	-40,049	-47,016	-53,292	-49,256	-42,246	-42,240	-42,240	-42,238	-42,254	-48,468	-43,889	-46,420	-45,339	-45,356	-48,946	-51,730	-54,616	-67,080	-114,317
46.87	112.24	-68.88	-266.56	81.44	43.19	-89.73	-21.75	-8.08	6.3	32.79	23.89	111.65	-114.55	181.03	-43.64	281.93	-220.56	205.26	-7.34
83,850	64,350	16,608	33,759	99,075	105,007	28,869	50,385	-17,210	48,146	104,884	83,272	70,431	25,420	144,036	128,114	62,544	47,148	467,245	-134,030
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

API Docs Get API Key

Daiichi Sankyo Co Stock Quarterly Figures

REVENUE (B JPY)

REVENUE GROWTH (%)

GROSS MARGIN (%)

GROSS INCOME (B JPY)

NET INCOME (B JPY)

NET INCOME GROWTH (%)

DIVIDEND (JPY)DIV. (JPY)

DIVIDEND GROWTH (%)DIV. GROWTH (%)

SHARES (B)

2005 QNaN	2007 Q1	2007 Q2	2007 Q3	2008 Q1	2008 Q2	2008 Q3	2009 Q1	2009 Q2	2009 Q3	2010 Q1	2010 Q2	2010 Q3	2011 Q1	2011 Q2	2011 Q3	2011 Q4	2012 Q1	2012 Q2	2012 Q3	2012 Q4	2013 Q1	2013 Q2	2013 Q3	2013 Q4	2014 Q1	2014 Q2	2014 Q3	2014 Q4	2015 Q1	2015 Q2	2015 Q3	2015 Q4	2016 Q1	2016 Q2	2016 Q3	2016 Q4	2017 Q1	2017 Q2	2017 Q3	2017 Q4	2018 Q1	2018 Q2	2018 Q3	2018 Q4	2019 Q1	2019 Q2	2019 Q3	2019 Q4	2020 Q1	2020 Q2	2020 Q3	2020 Q4	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2026 Q1	2026 Q2	2026 Q3	2026 Q4e	2027 Q1e	2027 Q2e	2027 Q3e	2027 Q4e
252.23	270.55	215.29	244.81	235.54	208.17	252.14	203.73	202.59	221.3	227.12	243.45	255.09	256.43	242.46	249.17	219.31	231.66	224.38	240.36	242.27	242.62	241.55	261.46	249.03	252.64	264.13	288.77	93.59	213.71	215.88	264.81	81.2	238.42	240.36	279.78	227.89	240.97	217.04	276.39	220.72	239.1	230.29	271.65	219.15	225.74	221.11	256.23	226.64	249.24	230.33	277.46	224.76	236.95	243.22	258.62	223.73	264.07	265.9	281	233.93	280.32	327.48	340.48	330.2	350.84	375.51	446.93	428.42	436.18	446.55	484.84	518.69	474.6	500.76	558.11	592.62	538.33	557.52	593.88	663.57
–	7.26	-20.42	13.71	-3.78	-11.62	21.12	-19.20	-0.56	9.23	2.63	7.19	4.79	0.52	-5.45	2.77	-11.98	5.63	-3.15	7.12	0.80	0.14	-0.44	8.24	-4.76	1.45	4.55	9.33	-67.59	128.33	1.02	22.66	-69.33	193.60	0.81	16.40	-18.55	5.74	-9.93	27.35	-20.14	8.33	-3.68	17.96	-19.33	3.01	-2.05	15.88	-11.55	9.97	-7.59	20.46	-18.99	5.42	2.65	6.33	-13.49	18.03	0.69	5.68	-16.75	19.83	16.82	3.97	-3.02	6.25	7.03	19.02	-4.14	1.81	2.38	8.57	6.98	-8.50	5.51	11.45	6.18	-9.16	3.56	6.52	11.73
68.90	72.80	70.07	71.27	75.44	73.41	72.82	76.13	75.81	75.99	72.48	69.30	70.44	75.02	69.30	70.07	68.71	74.14	69.27	70.18	71.90	72.53	68.05	66.95	56.53	65.33	67.27	64.52	93.22	69.78	69.33	65.96	61.25	68.98	68.81	68.27	64.50	67.79	67.91	65.82	51.24	66.51	66.57	63.78	58.67	62.46	62.96	61.65	56.01	64.73	61.27	71.46	61.33	65.30	64.49	66.04	63.40	67.75	67.13	67.28	62.03	73.32	74.12	71.22	67.90	73.30	74.77	72.62	75.59	78.21	78.05	73.52	81.81	80.54	68.85	78.81	74.22	81.70	78.89	74.06	66.28
173.8	196.96	150.86	174.47	177.69	152.82	183.61	155.09	153.59	168.16	164.61	168.71	179.68	192.37	168.02	174.6	150.7	171.75	155.43	168.69	174.21	175.97	164.38	175.05	140.77	165.04	177.67	186.32	87.25	149.12	149.68	174.67	49.74	164.46	165.39	190.99	146.99	163.35	147.39	181.92	113.09	159.03	153.31	173.26	128.58	140.99	139.21	157.97	126.93	161.34	141.13	198.28	137.84	154.74	156.86	170.78	141.85	178.92	178.49	189.06	145.1	205.52	242.71	242.51	224.22	257.16	280.77	324.58	323.86	341.13	348.52	356.46	424.35	382.25	344.78	439.83	439.83	439.83	439.83	439.83	439.83
31.54	48	18.89	10.81	41.41	18.83	36.18	25.08	8.89	-331.8	-6.44	25.13	20.55	33.07	19.08	27.51	-9.54	25.31	11.74	-19.5	-7.16	20.41	3.95	27.14	42.48	15.02	18.45	37.96	-10.49	19.99	30.34	51.91	219.89	34.93	35.76	40.03	-28.45	30.6	18.39	39.2	-34.72	29.15	5.13	38.32	-12.32	23.95	20.06	34.78	14.61	43.35	21.08	69.86	-5.21	31.86	19.81	24.14	0.15	35.22	27.25	31.85	-27.35	18.85	39.46	28.39	22.49	57.01	39.99	66.56	37.17	85.38	61.29	61.93	87.15	85.5	45.31	86.63	102.58	111.15	132.23	99.65	139.9
–	52.18	-60.66	-42.77	283.19	-54.52	92.10	-30.67	-64.55	-3,831.87	-98.06	-490.28	-18.21	60.92	-42.31	44.17	-134.68	-365.29	-53.63	-266.18	-63.29	-385.04	-80.64	587.19	56.51	-64.63	22.83	105.68	-127.64	-290.49	51.80	71.09	323.62	-84.11	2.38	11.93	-171.06	-207.58	-39.92	113.19	-188.57	-183.98	-82.42	647.79	-132.15	-294.41	-16.23	73.37	-58.00	196.69	-51.37	231.41	-107.45	-711.81	-37.82	21.86	-99.37	23,071.05	-22.64	16.91	-185.85	-168.94	109.31	-28.05	-20.79	153.53	-29.85	66.42	-44.16	129.73	-28.22	1.04	40.73	-1.90	-47.00	91.18	18.41	8.36	18.97	-24.64	40.38
-	-	-	10.00	10.00	-	11.67	11.67	-	13.33	13.33	-	10.00	10.00	-	10.00	-	10.00	-	10.00	-	10.00	-	10.00	-	10.00	-	10.00	-	10.00	-	10.00	-	10.00	-	10.00	-	10.00	-	11.67	-	11.67	-	11.67	-	11.67	-	11.67	-	11.67	-	11.67	-	11.67	-	13.50	-	13.50	-	13.50	-	13.50	-	15.00	-	15.00	-	20.00	-	30.00	-	30.00	-	30.00	-	39.00	-	-	-	-	-
–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
0.73	0.73	0.74	0.73	0.73	0.73	0.72	0.72	0.71	0.7	0.7	0.71	0.7	0.7	0.71	0.7	0.7	0.71	0.71	0.7	0.71	0.71	0.71	0.71	0.72	0.71	0.71	0.71	0.7	0.7	0.71	0.71	0.7	0.7	0.69	0.69	0.68	0.69	0.68	0.67	0.66	0.67	0.67	0.66	0.65	0.65	0.65	0.65	0.65	1.95	1.95	1.95	1.94	1.95	1.95	1.94	1.93	1.92	1.92	1.92	1.92	1.92	1.92	1.92	1.92	1.92	1.92	1.92	1.92	1.91	1.9	1.89	1.88	1.86	1.85	1.85	1.85	1.85	1.85	1.85	1.85

Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Gross Margin

EBIT and EBIT Margin

Net Income and Earnings Per Share (EPS)

Shares Outstanding

Analyst Estimates

API Docs Get API Key

Daiichi Sankyo Co stock margins

The Daiichi Sankyo Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Daiichi Sankyo Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Daiichi Sankyo Co.

3 Years
5 Years
10 Years
25 Years
Max

Gross margin

EBIT margin

Profit margin

Details

API Docs Get API Key

Daiichi Sankyo Co Stock Sales Revenue, EBIT, Earnings per Share

The Daiichi Sankyo Co earnings per share therefore indicates how much revenue Daiichi Sankyo Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

3 Years
5 Years
10 Years
25 Years
Max

Sales per Share

EBIT per share

Earnings per Share

Details

API Docs Get API Key

Daiichi Sankyo Co business model

Daiichi Sankyo Co Ltd is a company specialized in the production of medicines. The company was founded in 2005 and was formed from the merger of two Japanese pharmaceutical companies. However, the history of Daiichi Sankyo dates back to 1899 when the Daiichi Group and Sankyo Renkyu merged to form a cooperative. Both companies had been active in the pharmaceutical business since the 1960s and were specialized in the development and production of drugs. Daiichi Sankyo's business model is focused on developing and globally marketing innovative drugs. The company focuses on researching and marketing drugs for the treatment of cancer, cardiovascular diseases, and infectious diseases. Daiichi Sankyo is divided into different divisions. The pharmaceutical division is the company's most important business segment. Here, drugs for various applications are developed and produced, including medications for the therapy of cancer, cardiovascular diseases, and infections. Another division is the medical devices division. Here, medical devices such as catheters and stents for the treatment of cardiovascular diseases, as well as endoscopic devices for the diagnosis and therapy of gastrointestinal diseases, are manufactured. Another important area is the diagnostics division. Here, diagnostic test systems for various applications are developed and manufactured. Some of Daiichi Sankyo's best-known products include the cancer drug Trastuzumab Emtansin and the anticoagulant drug Prasugrel. Daiichi Sankyo is a globally operating company headquartered in Tokyo, Japan. In addition, the company has branches in North, Central, and South America, Europe, Asia, and Oceania. The company places great importance on research and development and participates in numerous collaborations and partnerships with universities and other companies. The goal is to constantly develop new groundbreaking drugs and contribute to the improvement of disease treatment. Overall, Daiichi Sankyo employs approximately 15,000 people worldwide and generates an annual revenue of around 8 billion euros. The company is thus one of the leading companies in the pharmaceutical and medical technology industry and will remain an important player in the global healthcare market in the future.

API Docs Get API Key

Daiichi Sankyo Co SWOT Analysis

Strengths

Daiichi Sankyo Co Ltd possesses several strengths that contribute to its success in the pharmaceutical industry:

Strong brand reputation and recognition globally
Diversified portfolio of products across therapeutic areas
Robust research and development capabilities
Global presence with a strong foothold in key markets
Strong financial position and healthy revenue growth

Weaknesses

Despite its strengths, Daiichi Sankyo Co Ltd also faces certain weaknesses that pose challenges to its growth:

Overreliance on a few key products for a significant portion of revenue
Limited market share in certain regions
High competition within the pharmaceutical industry
Dependency on external suppliers for raw materials
Regulatory hurdles in entering new markets

Opportunities

There are several opportunities that Daiichi Sankyo Co Ltd can capitalize on to further expand its business:

Increasing demand for innovative pharmaceutical solutions
Growing aging population in many countries
Expansion into emerging markets with high growth potential
Strategic collaborations and partnerships
Advancements in technology for drug discovery and development

Threats

Daiichi Sankyo Co Ltd faces certain threats that need to be carefully addressed to mitigate potential risks:

Intense competition from generic drug manufacturers
Stringent regulations and increasing pricing pressures
Economic downturns impacting consumer spending on healthcare
Rapidly evolving healthcare landscape and changing patient preferences
Intellectual property infringements and counterfeit drugs

API Docs Get API Key

Daiichi Sankyo Co Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

API Docs Get API Key

Daiichi Sankyo Co historical P/E ratio, EBIT multiple, and P/S ratio

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Daiichi Sankyo Co's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Daiichi Sankyo Co's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Daiichi Sankyo Co's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Daiichi Sankyo Co grows earnings faster than its peers.

API Docs Get API Key

Daiichi Sankyo Co annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

API Docs Get API Key

Daiichi Sankyo Co shares outstanding

The number of shares was Daiichi Sankyo Co in 2025 — This indicates how many shares 1.897 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

3 Years
5 Years
10 Years
25 Years
Max

Number of stocks

Details

API Docs Get API Key

Daiichi Sankyo Co stock splits

In Daiichi Sankyo Co's history, there have been no stock splits.

API Docs Get API Key

Daiichi Sankyo Co Dividend History

21 years of dividend payments · 4 consecutive increases

YearAnnual DividendYoY ChangePayments

202639JPYYTD—1×

Mar 30, 202639JPY 0.0%1/1

202569JPY↑ 15.0%2×

Mar 28, 202530JPY 0.0%1/2

Sep 29, 202539JPY↑ 30.0%2/2

202460JPY↑ 71.4%2×

202335JPY↑ 22.8%2×

202228.5JPY↑ 5.6%2×

202127JPY↓ 44.3%2×

202048.5JPY↓ 30.7%2×

201970JPY 0.0%2×

201870JPY 0.0%2×

201770JPY↑ 7.7%2×

API Docs Get API Key

Daiichi Sankyo Co dividend history and estimates

In 2025, Daiichi Sankyo Co paid a dividend amounting to 69 JPY. Dividend means that Daiichi Sankyo Co distributes a portion of its profits to its owners.

3 Years
5 Years
10 Years
25 Years
Max

Dividend

Dividend (Estimate)

Details

API Docs Get API Key

Daiichi Sankyo Co dividend payout ratio

In 2025, Daiichi Sankyo Co had a payout ratio of 71.89%. The payout ratio indicates the percentage of the company's profits that Daiichi Sankyo Co distributes as dividends.

3 Years
5 Years
10 Years
25 Years
Max

Payout ratio

Details

API Docs Get API Key

Current Daiichi Sankyo Co forecasts and price targets in March 2026

Δ MOM Price Target	3.57 %
Buy	90.48 % (19)
Hold	9.52 % (2)
Sell	null % (0)
12M Price Target	5,508.00
Last Price	20.61
Currency	JPY
12M Return Potential	26,624.89 %
LTM Return	0 %

API Docs Get API Key

Daiichi Sankyo Co Earnings Estimates

Date	EPS estimate	Revenue Estimate	Quarterly report
4/25/2024	4.43JPY	399.94 BJPY	2024 Q4
1/29/2024	16.62JPY	408.88 BJPY	2024 Q3
7/27/2023	27.98JPY	345.1 BJPY	2024 Q1
4/25/2023	-4.85JPY	305.74 BJPY	2023 Q4
1/30/2023	19.35JPY	331.42 BJPY	2023 Q3
10/31/2022	14.11JPY	289.98 BJPY	2023 Q2
7/29/2022	12.79JPY	266.4 BJPY	2023 Q1
4/27/2022	-7.97JPY	241.73 BJPY	2022 Q4
1/31/2022	8.82JPY	261.01 BJPY	2022 Q3
10/29/2021	10.86JPY	257.54 BJPY	2022 Q2
7/30/2021	11.88JPY	245.37 BJPY	2022 Q1
4/27/2021	-12.05JPY	230.03 BJPY	2021 Q4
1/29/2021	11.36JPY	261.69 BJPY	2021 Q3
10/30/2020	7.14JPY	234.58 BJPY	2021 Q2
7/31/2020	13.84JPY	241.11 BJPY	2021 Q1
4/27/2020	-11.97JPY	223.97 BJPY	2020 Q4
1/31/2020	16.26JPY	269.08 BJPY	2020 Q3
10/31/2019	12.54JPY	236.35 BJPY	2020 Q2
7/31/2019	10.49JPY	225.36 BJPY	2020 Q1
4/25/2019	-6.17JPY	217.68 BJPY	2019 Q4
1/31/2019	12.66JPY	261.47 BJPY	2019 Q3
10/31/2018	8.61JPY	222.32 BJPY	2019 Q2
7/31/2018	9.39JPY	229.95 BJPY	2019 Q1
4/27/2018	-3.42JPY	227.04 BJPY	2018 Q4
1/31/2018	11.35JPY	261.12 BJPY	2018 Q3
10/31/2017	3.88JPY	232.11 BJPY	2018 Q2
7/31/2017	13.74JPY	235.28 BJPY	2018 Q1
5/11/2017	-5.89JPY	216.58 BJPY	2017 Q4
1/31/2017	10.71JPY	252 BJPY	2017 Q3
10/31/2016	10.58JPY	229.7 BJPY	2017 Q2
7/29/2016	10.66JPY	225.5 BJPY	2017 Q1
5/12/2016	-13.22JPY	226.57 BJPY	2016 Q4
1/29/2016	9.28JPY	263.24 BJPY	2016 Q3
10/30/2015	10.12JPY	240.84 BJPY	2016 Q2
7/31/2015	10.47JPY	234.16 BJPY	2016 Q1
1/30/2015	3.5JPY	263.6 BJPY	2015 Q3
10/31/2014	3.97JPY	273.59 BJPY	2015 Q2
7/31/2014	9.43JPY	216.56 BJPY	2015 Q1
1/31/2014	9.9JPY	272.32 BJPY	2014 Q3
10/31/2013	7.91JPY	268.87 BJPY	2014 Q2
7/31/2013	7.81JPY	252.73 BJPY	2014 Q1
1/31/2013	3.27JPY	247.86 BJPY	2013 Q3
10/31/2012	0.21JPY	230.58 BJPY	2013 Q2
7/31/2012	11.36JPY	246.57 BJPY	2013 Q1
5/11/2012	-0.47JPY	240.8 BJPY	2012 Q4
1/31/2012	12.12JPY	251.27 BJPY	2012 Q3
10/31/2011	4.63JPY	241.87 BJPY	2012 Q2
7/29/2011	8.2JPY	232.46 BJPY	2012 Q1
5/12/2011	-0.18JPY	224.93 BJPY	2011 Q4
1/31/2011	7.84JPY	251.6 BJPY	2011 Q3
10/29/2010	3.27JPY	252.73 BJPY	2011 Q2
7/30/2010	7.14JPY	254.26 BJPY	2011 Q1

EESG©

Eulerpool ESG Scorecard© for the Daiichi Sankyo Co stock

92/100

Environment

Social

Governance

Environment

Scope 1 - Direct Emissions85,245

Scope 2 - Indirect emissions from purchased energy23,994

Scope 3 - Indirect emissions within the value chain4,408,736

Total CO₂ emissions109,239

CO₂ reduction strategy

Coal energy

Nuclear power

Animal experiments

Fur & Leather—

Pesticides—

Palm Oil—

Tobacco

Genetically modified organisms

Climate concept—

Sustainable forestry—

Recycling regulations

Environmentally friendly packaging

Hazardous substances

Fuel consumption and efficiency

Water consumption and efficiency

Social

Percentage of female employees41

Percentage of women in management—

Percentage of Asian employees—

Share of Asian management—

Percentage of Hispanic/Latino employees—

Hispano/Latino Management share—

Percentage of Black employees—

Black Management Share—

Percentage of white employees—

White Management Share—

Adult content

Alcohol

Weapons—

Firearms

Gambling

Military contracts

Human rights concept

Privacy concept—

Occupational health and safety

Catholic

Governance (Corporate Governance)

Environmental reporting

Stakeholder Engagement

Call Back Policies

Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

API Docs Get API Key

Daiichi Sankyo Co shareholders

%	Name	Stocks	Change	Date
4.73870%	Capital Research Global Investors	89,914,541	-25,947,994	4/30/2025
4.65372%	Nomura Asset Management Co., Ltd.	88,302,079	-914,200	7/31/2025
4.52517%	Nippon Life Insurance Company	85,863,000		3/31/2025
2.98306%	The Vanguard Group, Inc.	56,602,241	-55,700	7/31/2025
2.96700%	Asset Management One Co., Ltd.	56,297,400	-1,336,200	7/31/2025
2.17804%	Nikko Asset Management Co., Ltd.	41,327,193	-727,200	7/31/2025
2.10122%	Daiwa Asset Management Co., Ltd.	39,869,748	-16,904	7/31/2025
2.04998%	BlackRock Japan Co., Ltd.	38,897,400	+38,234,800	10/15/2024
1.92993%	BlackRock Fund Advisors	36,619,601	+36,578,301	10/15/2024
1.47682%	Norges Bank Investment Management (NBIM)	28,022,000	+403,000	3/31/2025
1.46952%	Wellington Management Company, LLP	27,883,425	-8,283,958	6/30/2025
1.31830%	Mizuho Bank, Ltd.	25,014,130		7/31/2025
1.23210%	BlackRock Institutional Trust Company, N.A.	23,378,534	-23,689,109	10/15/2024
1.02274%	Nuveen LLC	19,406,040	+67,200	7/31/2025
0.92267%	Mitsubishi UFJ Asset Management Co., Ltd.	17,507,270	-33,982	7/31/2025
0.82135%	MFS Investment Management	15,584,800	+1,831,900	6/30/2025
0.80591%	BlackRock Asset Management Ireland Limited	15,291,746	+15,291,746	10/15/2024
0.75465%	Geode Capital Management, L.L.C.	14,319,072	-21,769	6/30/2025
0.68008%	BlackRock Advisors (UK) Limited	12,904,146	-71,200	7/31/2025
0.49784%	BlackRock Investment Management (UK) Ltd.	9,446,252	-368,485	10/15/2024
0.45185%	JP Morgan Asset Management	8,573,583	+360,700	7/31/2025
0.44722%	Mizuho Trust & Banking Co., Ltd.	8,485,870		7/31/2025
0.40328%	Goldman Sachs Asset Management, L.P.	7,651,964		7/31/2025
0.36159%	BlackRock (Netherlands) B.V.	6,861,045	+6,861,045	10/15/2024
0.34459%	Fidelity Management & Research Company LLC	6,538,376	+186,700	7/31/2025
0.31400%	BlackRock Financial Management, Inc.	5,958,000		7/31/2025
0.29022%	Mizuho Securities Co., Ltd.	5,506,777	+1,898,792	7/31/2025
0.29013%	DWS Investments UK Limited	5,505,098	+22,609	7/31/2025
0.28990%	Charles Schwab Investment Management, Inc.	5,500,732	+12,285	7/31/2025
0.23986%	Amundi Asset Management, SAS	4,551,323	-83,000	7/31/2025
0.23595%	APG Asset Management N.V.	4,477,022	+130,444	12/31/2024
0.22854%	Carmignac Gestion	4,336,468	+16,510	5/31/2025
0.22435%	BlackRock (Luxembourg) S.A.	4,257,006	+3,451,606	10/15/2024
0.21945%	M&G Investment Management Ltd.	4,164,000	+30,500	6/30/2025
0.21314%	Capital International, Inc.	4,044,200	-232,586	4/30/2025
0.20738%	Invesco Advisers, Inc.	3,934,911	+728	7/31/2025
0.20014%	DWS Investment GmbH	3,797,562	+2,057	7/31/2025
0.19877%	UBS Asset Management (UK) Ltd.	3,771,533	+148,015	7/31/2025
0.19820%	California State Teachers Retirement System	3,760,738	+1,218,329	6/30/2024
0.19795%	State Street Global Advisors (US)	3,756,047	+9,733	7/31/2025
0.19775%	RBC Global Asset Management (Asia) Limited	3,752,298	+431,400	6/30/2025
0.18720%	BlackRock Investment Management, LLC	3,551,957	+1,791,271	10/15/2024
0.17759%	California Public Employees' Retirement System	3,369,698	-281,340	6/30/2024
0.17159%	HSBC Global Asset Management (UK) Limited	3,255,753	+55,737	6/30/2025
0.17023%	Medipal Holdings Corp	3,230,089	-1,850,000	3/31/2024
0.16663%	Aviva Investors Global Services Limited	3,161,728	+8,968	6/30/2025
0.16032%	CPP Investment Board	3,042,000	-885,000	3/31/2024
0.15808%	Toray Industries Inc	2,999,583		3/31/2024
0.14650%	BlackRock Advisors, LLC	2,779,723	+2,730,123	10/15/2024
0.14561%	OrbiMed Advisors, LLC	2,762,850		4/30/2025
0.14327%	Royal London Asset Management Ltd.	2,718,500	+36,100	6/30/2025
0.14200%	TD Asset Management Inc.	2,694,407	+5,100	6/30/2025
0.14179%	AQR Capital Management, LLC	2,690,406	+1,622,400	6/30/2025
0.13823%	Janus Henderson Investors	2,622,800	+1,797,800	6/30/2025
0.12629%	Handelsbanken Kapitalförvaltning AB	2,396,222	-28,800	6/30/2025
0.12368%	Legal & General Investment Management Ltd.	2,346,793	-28,100	7/31/2025
0.11931%	BlackRock Investment Management (Australia) Ltd.	2,263,767	+2,147,167	10/15/2024
0.11883%	UBS Fund Management (Switzerland) AG	2,254,728	-1,600	7/31/2025
0.11704%	Mellon Investments Corporation	2,220,711	-43,500	7/31/2025
0.11645%	BNP Paribas Asset Management USA, Inc.	2,209,500		6/30/2025
0.11348%	Nordea Funds Oy	2,153,300	+28,200	6/30/2025
0.11018%	State Street Global Advisors (UK) Ltd.	2,090,704	+41,000	7/31/2025
0.10923%	BlackRock Asset Management Canada Limited	2,072,543	+794,643	10/15/2024
0.10042%	MFS Institutional Advisors, Inc	1,905,440	-135,400	6/30/2025
0.09139%	Kissei Pharmaceutical Co Ltd	1,734,000		3/31/2024
0.09027%	Northern Trust Investments, Inc.	1,712,867	+6,800	7/31/2025
0.08630%	Rheos Capital Works Inc.	1,637,547	+482,446	9/30/2024
0.07920%	Nissay Asset Management Corp.	1,502,819	+97,059	2/28/2025
0.07728%	Capital World Investors	1,466,300	+1,420,300	6/30/2025
0.07581%	Schroder Investment Management Ltd. (SIM)	1,438,400	-26,400	6/30/2025
0.07152%	JPMorgan Asset Management (Asia Pacific) Limited	1,357,000		6/30/2025
0.07115%	Caixabank Asset Management SGIIC, S.A.U.	1,350,084		5/31/2025
0.07041%	Northern Trust Global Investments Limited	1,336,037	+83,937	6/30/2025
0.06909%	Capfi Delen Asset Management	1,311,000	-5,000	3/31/2025
0.06732%	Cardano Asset Management NV	1,277,451	-40,036	6/30/2025
0.06730%	BNP Paribas Asset Management UK Limited	1,277,000	+258,700	6/30/2025
0.06595%	Nomura Asset Management (UK) Ltd.	1,251,300	+4	1/31/2025
0.06462%	Dimensional Fund Advisors, L.P.	1,226,138	-9,000	7/31/2025
0.06436%	Sumitomo Mitsui DS Asset Management Company, Limited	1,221,204	+92,500	7/31/2025
0.06311%	UBS Asset Management (Switzerland)	1,197,515	-6,800	7/31/2025
0.06241%	Norinchukin Zenkyoren Asset Management Co., Ltd.	1,184,235	-12,000	7/31/2025
0.05908%	Zürcher Kantonalbank (Asset Management)	1,121,077	+4,000	6/30/2025
0.05765%	Candriam Luxembourg S.A.	1,093,898	-12,600	6/30/2025
0.05691%	Deka Investment GmbH	1,079,883		7/31/2025
0.05466%	SEB Investment Management AB	1,037,123	-808	6/30/2025
0.05465%	Vanguard Investments Australia Ltd.	1,036,921	-5,470	6/30/2025
0.05347%	Franklin Templeton Portfolio Advisors, Inc	1,014,600	+4,900	7/31/2025
0.05184%	JPMorgan Asset Management U.K. Limited	983,600	-34,600	6/30/2025
0.04839%	Storebrand Kapitalforvaltning AS	918,102	+5,000	6/30/2025
0.04806%	Vanguard Global Advisers LLC	911,850	-19,500	6/30/2025
0.04785%	DBX Advisors LLC.	907,938	-5,800	7/31/2025
0.04743%	Hitachi Ltd	900,000		3/31/2024
0.04656%	PGGM Vermogensbeheer B.V.	883,425	-148,219	3/31/2025
0.04243%	Danske Bank Asset Management	805,118	-1	6/30/2025
0.04243%	Matthews International Capital Management, L.L.C.	805,000	-300	7/31/2025
0.04224%	BMO Asset Management Inc.	801,447		7/31/2025
0.04215%	Medical Strategy GmbH	799,800	-209,200	11/30/2024
0.04158%	Första AP-Fonden	789,000	+340,300	12/31/2024
0.04024%	Jyske Invest Fund Management A/S	763,511	+113,700	6/30/2025
0.03891%	Florida State Board of Administration	738,310	+177,495	3/31/2025

...

API Docs Get API Key

Daiichi Sankyo Co Executives and Management Board

Mr. Sunao Manabe

(69)

Chairman of the Board, Chairman of the Executive Board, Chief Executive Officer, Representative Director · since 2012

Compensation385 MJPY

Compensation385 M JPY

Mr. Hiroyuki Okuzawa

(61)

President, Executive President, Chief Operating Officer, Representative Director · since 2018

252 MJPY

Compensation252 M JPY

Mr. Shoji Hirashima

(63)

Senior Managing Executive Officer, Manager of Japan Business Unit, Representative Director

166 MJPY

Compensation166 M JPY

Mr. Takashi Fukuoka

(63)

Senior Managing Executive Officer, Head of Global Corporate Strategy, CStO, Director

147 MJPY

Compensation147 M JPY

Mr. Takashi Matsumoto

(60)

Chief Human Resource Officer, Managing Executive Officer, Head of Global HR, Director

API Docs Get API Key

Daiichi Sankyo Co Research

Soon

Deep-dive analyses, investment theses, and proprietary research — curated by Eulerpool.

Research reports are coming soon

We're building institutional-grade equity research for Daiichi Sankyo Co and thousands of other companies.

Most common questions regarding Daiichi Sankyo Co

The business model of Daiichi Sankyo Co Ltd revolves around the research, development, manufacturing, and marketing of pharmaceutical products. As a global pharmaceutical company, Daiichi Sankyo focuses on innovative solutions in the areas of cardiovascular, oncology, and immunology. With a commitment to improving human health and well-being, Daiichi Sankyo strives to deliver high-quality medications that address unmet medical needs. Through strategic collaborations and acquisitions, the company aims to expand its product portfolio and reach a wider patient population. Daiichi Sankyo's business model centers on providing effective and safe healthcare solutions while contributing to scientific advancements in the field of pharmaceuticals.

Daiichi Sankyo Co Ltd is a globally leading company in the pharmaceutical industry, focusing on the research and development of new innovative drugs. The company was formed in 2005 through the merger of two Japanese companies, Daiichi Pharmaceutical Co Ltd and Sankyo Co Ltd, and is headquartered in Tokyo, Japan. Daiichi Sankyo's business model consists of three main divisions: Pharma, Generics, and Consumer Healthcare. In the Pharma division, the company develops and distributes innovative drugs in the areas of oncology, cardiovascular diseases, pain management, and infectious diseases. Daiichi Sankyo utilizes a combination of preclinical research, clinical trials, and partnerships with other companies in the industry. An important component of Daiichi Sankyo's business model is the Generics division, where the company develops and distributes lower-cost versions of existing drugs. With this strategy, the company aims to expand its reach and generate higher revenue without bearing the high costs of researching and developing new medications. Daiichi Sankyo's Consumer Healthcare division includes products such as dietary supplements, vitamins, and medical foods. With this segment of the business, the company also aims to enter this market segment and expand its reach to a wider range of products. In the field of oncology, Daiichi Sankyo has developed and marketed some important drugs, including the cancer drugs Lonsurf and Enhertu. The company has also formed partnerships with other companies in the field of cancer research to create synergies and develop the best treatment options. In the cardiovascular diseases division, Daiichi Sankyo develops products such as the blood pressure medication Olmesartan and the antiplatelet drug Prasugrel. The company has also been involved in the development and marketing of the pain medication Celecoxib, used in the treatment of arthritis and other pain conditions. In pain management, Daiichi Sankyo develops the pain medication Tapentadol, used in the treatment of severe and chronic pain. The company has also formed partnerships with other companies in the field of pain management to expand its product range and provide better treatment options for patients. Overall, Daiichi Sankyo pursues a broad business model that includes the development of innovative products in various segments of the pharmaceutical industry, as well as the marketing of lower-cost versions of existing medications and the marketing of products in the Consumer Healthcare sector. With a strong focus on research and development, partnerships, and collaboration with other companies in the industry, the company is well positioned to continue expanding in the pharmaceutical industry and develop innovative solutions for patient healthcare.

API Docs Get API Key

Fair ValuePRO

2,654.69 JPY

Over-/UndervaluationPRO

25.0% undervalued

Expected Return

21.19 %

Sector

Health

Industry

Pharmaceuticals

Number of shares

1,897,453,000

Employees

15,348

Revenue per Employee

122.9 M JPY

Revenue growth Ø5 years

14.4 %

EBIT growth Ø5 years

39.08 %

Net Income growth Ø5 years

31.24 %

Website daiichisankyo.co.jp

Country

Japan 🇯🇵

Currency

JPY

Initial public offering

Sep 28, 2005

ISIN

JP3475350009

Cusip

J11257102

Sedol

B0J7D91

Market capitalization

5.51 T JPYMega Cap

52-Week Range

2,844–3,064JPY

Daiichi Sankyo Co Directors Dealings

Quality Investing

Details

9 / 10

Sales growth (10Y) > 5%

Revenue growth (3Y) > 5 %

EBIT growth (10Y) > 5%

EBIT growth (3Y) > 5 %

Net debt < 4x EBIT

Profitable since 10Y+

EBIT Drawdown (10Y) < 50%

Return on Equity (ROE) > 15%

ROCE > 15%

Return Expectation > 10%

PEG

1.39

P/E ratio

18.31

P/Ee 2026

16.77

P/Ee 2027

14.02

P/Ee 2028

11.58

P/S

2.87

P/Se

2.49

EV/EBIT

15.14

P/B Ratio

3.39

ROE (Return on Equity)

18.22 %

ROA (Return on Assets)

8.56 %

ROCE (Return on Capital Employed)

20.45 %

ROIC (Return on Invested Capital)

25.96 %

Gross Margin

77.96 %

EBIT Margin

17.6 %

Net Margin

15.68 %

EPS (Earnings Per Share)

155.87 JPY

Net Debt / EBIT

-1.46

Debt/Equity

0.1

Dividend

69 JPY

Dividend yield

2.42 %

Est. Dividend Yield

1.37 %

Payout Ratio

71.89 %

Dividend growth Ø5Y

6.47 %

Dividend payments per year

Dividend paid since

20 years+

Dividend not reduced since

0 years

Dividend increased since

0 years

Dividend withholding tax

15.32 %

Last updated Mar 12, 2026, 10:14 AM

Daiichi Sankyo Co Peer Group

Astellas Pharma Inc

Chugai Pharmaceutical Co Ltd

Otsuka Holdings Co Ltd

Eisai Co Ltd

Shionogi & Co Ltd

Takeda Pharmaceutical Co Ltd

Daiichi Sankyo Co Ticker

DÜSSELDORF · D4S.DUFRANKFURT · D4S.FJPX · 4568.TMUNICH · D4S.MUPNK · DSKYF

Daiichi Sankyo Co FIGI

4568:JP · BBG000BWPLT14568:JT · BBG000BWPMB84568:JJ · BBG000BWPS894568:JE · BBG000BWPT414568:JI · BBG000BWPTF9D4S:GR · BBG000DXRM40D4S:GF · BBG000DXRMJ4D4S:GD · BBG000DXRMZ6D4S:GS · BBG000DXRNN7D4S:GM · BBG000DXRNW7D4S:GB · BBG000DXRP70D4S:GI · BBG000DXRQL2DSKYF:US · BBG000JG7CY2DSKYF:PQ · BBG000JG7QS8DSKYF:UV · BBG000JG7T114568:JU · BBG002QKCFJ54568JPY:EO · BBG005QKW3584568JPY:XH · BBG005QKW3854568JPY:XF · BBG005QKW3B14568JPY:XE · BBG005QKW3D94568JPY:XJ · BBG005QKW3F74568JPY:XL · BBG005QKW3H54568JPY:XG · BBG005QKW3J34568JPY:XO · BBG005QKW3K14568JPY:XS · BBG005QKW3Q54568JPY:XA · BBG005QKW3R44568JPY:E1 · BBG005QKW3S34568JPY:XT · BBG005QKW3T24568JPY:XW · BBG005QKW3V94568JPY:XU · BBG005QKW3W84568JPY:XV · BBG005QKW3Y64568JPY:EU · BBG005QKW4W64568:JW · BBG00875HD42D4S:QT · BBG00D0NBX054568EUR:EO · BBG00D0NQWZ34568EUR:XH · BBG00D0NQX544568EUR:XF · BBG00D0NQX904568EUR:XE · BBG00D0NQXD54568EUR:XJ · BBG00D0NQXF34568EUR:XL · BBG00D0NQXG24568EUR:XG · BBG00D0NQXH14568EUR:XO · BBG00D0NQXJ94568EUR:XS · BBG00D0NQXN44568EUR:XA · BBG00D0NQXP24568EUR:E1 · BBG00D0NQXQ14568EUR:XT · BBG00D0NQXR04568EUR:XW · BBG00D0NQXS94568EUR:XU · BBG00D0NQXT84568EUR:XV · BBG00D0NQXV54568EUR:EU · BBG00D0NQXX3D4S:GZ · BBG00FGWY4Q44568JPY:XX · BBG00JN850Y24568EUR:XX · BBG00JN8HR894568USD:X2 · BBG00K62KFT74568USD:XB · BBG00K62KFV44568USD:XH · BBG00K62KFX24568USD:XF · BBG00K62KFZ04568USD:XE · BBG00K62KG154568USD:XJ · BBG00K62KG244568USD:XL · BBG00K62KG334568USD:XG · BBG00K62KG424568USD:XO · BBG00K62KG514568USD:XS · BBG00K62KG974568USD:XA · BBG00K62KGB44568USD:E1 · BBG00K62KGC34568USD:XT · BBG00K62KGD24568USD:XW · BBG00K62KGF04568USD:XU · BBG00K62KGG94568USD:XV · BBG00K62KGH84568USD:XM · BBG00K62KGJ64568USD:XQ · BBG00K62KGL34568USD:XX · BBG00K62KGM24568USD:XZ · BBG00K62KGN14568USD:EU · BBG00K62KGQ8D4S:TH · BBG00PYS9PX44568JPY:X2 · BBG00Q6RTVL34568JPY:EP · BBG00QNTRT194568JPY:EZ · BBG00QNTRT37D4S:LA · BBG018H8BJ65D4S:LU · BBG018J1ZLS34568:JV · BBG0193R9M53D4S:BU · BBG01BPDCRM14568N:MM · BBG01C70D3584568N:MF · BBG01C70D3674568N:MU · BBG01C70D376

All fundamentals about Daiichi Sankyo Co

Our stock analysis for Daiichi Sankyo Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Daiichi Sankyo Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Daiichi Sankyo Co Revenue→

Daiichi Sankyo Co Net Income→

Daiichi Sankyo Co P/E→

Daiichi Sankyo Co P/S→

Daiichi Sankyo Co EBIT→

Daiichi Sankyo Co Dividend→

Daiichi Sankyo Co Directors Dealings→

Daiichi Sankyo Co Stocks→

Daiichi Sankyo Co Market capitalization→

Daiichi Sankyo Co Debt→

Daiichi Sankyo Co Liabilities→

Daiichi Sankyo Co Equity→